Your browser doesn't support javascript.
loading
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
Reuben, Alexandre; Gittelman, Rachel; Gao, Jianjun; Zhang, Jiexin; Yusko, Erik C; Wu, Chang-Jiun; Emerson, Ryan; Zhang, Jianhua; Tipton, Christopher; Li, Jun; Quek, Kelly; Gopalakrishnan, Vancheswaran; Chen, Runzhe; Vence, Luis M; Cascone, Tina; Vignali, Marissa; Fujimoto, Junya; Rodriguez-Canales, Jaime; Parra, Edwin R; Little, Latasha D; Gumbs, Curtis; Forget, Marie-Andrée; Federico, Lorenzo; Haymaker, Cara; Behrens, Carmen; Benzeno, Sharon; Bernatchez, Chantale; Sepesi, Boris; Gibbons, Don L; Wargo, Jennifer A; William, William N; Swisher, Stephen; Heymach, John V; Robins, Harlan; Lee, J Jack; Sharma, Padmanee; Allison, James P; Futreal, P Andrew; Wistuba, Ignacio I; Zhang, Jianjun.
Afiliação
  • Reuben A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gittelman R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gao J; Adaptive Biotechnologies, Seattle, Washington.
  • Zhang J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yusko EC; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wu CJ; Adaptive Biotechnologies, Seattle, Washington.
  • Emerson R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhang J; Adaptive Biotechnologies, Seattle, Washington.
  • Tipton C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li J; Adaptive Biotechnologies, Seattle, Washington.
  • Quek K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gopalakrishnan V; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chen R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vence LM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cascone T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vignali M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fujimoto J; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rodriguez-Canales J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Parra ER; Adaptive Biotechnologies, Seattle, Washington.
  • Little LD; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gumbs C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Forget MA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Federico L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Haymaker C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Behrens C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benzeno S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sepesi B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gibbons DL; Adaptive Biotechnologies, Seattle, Washington.
  • Wargo JA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • William WN; Department of Thoracic Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Swisher S; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Heymach JV; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Robins H; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lee JJ; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sharma P; Department of Thoracic Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Allison JP; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Futreal PA; Adaptive Biotechnologies, Seattle, Washington.
  • Wistuba II; Department of Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Zhang J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov ; 7(10): 1088-1097, 2017 10.
Article em En | MEDLINE | ID: mdl-28733428
ABSTRACT
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.

Significance:

The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088-97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Sequenciamento do Exoma / Neoplasias Pulmonares / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Sequenciamento do Exoma / Neoplasias Pulmonares / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2017 Tipo de documento: Article